Tiverton Asset Management LLC acquired a new stake in Agilent Technologies Inc (NYSE:A) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,415 shares of the medical research company’s stock, valued at approximately $329,000.

A number of other institutional investors have also bought and sold shares of the business. Artisan Partners Limited Partnership increased its stake in Agilent Technologies by 0.6% in the first quarter. Artisan Partners Limited Partnership now owns 5,858,087 shares of the medical research company’s stock valued at $470,873,000 after purchasing an additional 36,359 shares during the last quarter. FMR LLC raised its holdings in Agilent Technologies by 2.9% during the first quarter. FMR LLC now owns 5,635,232 shares of the medical research company’s stock worth $452,960,000 after purchasing an additional 159,653 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Agilent Technologies by 20.6% during the 1st quarter. American Century Companies Inc. now owns 4,928,415 shares of the medical research company’s stock worth $396,146,000 after buying an additional 840,850 shares during the last quarter. Findlay Park Partners LLP lifted its position in shares of Agilent Technologies by 51.9% during the 2nd quarter. Findlay Park Partners LLP now owns 4,500,000 shares of the medical research company’s stock worth $336,015,000 after buying an additional 1,538,234 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Agilent Technologies by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,234,035 shares of the medical research company’s stock worth $285,139,000 after buying an additional 285,330 shares during the last quarter.

Agilent Technologies stock traded up $1.87 during trading hours on Wednesday, reaching $76.64. 107,311 shares of the stock were exchanged, compared to its average volume of 2,508,173. The stock has a market cap of $22.96 billion, a P/E ratio of 27.46, a P/E/G ratio of 2.05 and a beta of 1.40. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.72 and a current ratio of 2.13. Agilent Technologies Inc has a 52-week low of $61.01 and a 52-week high of $82.27. The firm’s 50 day moving average is $70.14 and its 200 day moving average is $73.98.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 14th. The medical research company reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.04. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.24 billion. Agilent Technologies had a net margin of 21.06% and a return on equity of 20.00%. The business’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business earned $0.67 EPS. Equities research analysts expect that Agilent Technologies Inc will post 3.08 EPS for the current fiscal year.

In other news, Director Heidi Fields sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $70.96, for a total value of $283,840.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

A has been the subject of several research analyst reports. ValuEngine downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, July 12th. Piper Jaffray Companies raised their price objective on shares of Agilent Technologies from $83.00 to $86.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. Zacks Investment Research lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating and set a $75.00 price objective on the stock. in a research note on Monday, August 19th. Wolfe Research assumed coverage on shares of Agilent Technologies in a report on Thursday, May 30th. They issued a “peer perform” rating for the company. Finally, Robert W. Baird reiterated an “outperform” rating and set a $82.00 target price (up previously from $79.00) on shares of Agilent Technologies in a research note on Thursday, August 15th. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Agilent Technologies has an average rating of “Buy” and a consensus price target of $84.77.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: Marijuana Stocks

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.